Godavari Biorefineries
- Market cap
- ₹ 1,047 Cr.
- P/E
- 35.6x
- P/B
- 1.44x
- 52-week range
- 193.6 – 353
- ROE
- 4%
- ROCE
- 7%
- Dividend yield
- 0%
- Debt / equity
- 0.67
- Sector
- Diversified FMCG
- Industry
- Diversified FMCG
- Listed on
- NSE, BSE
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Diversified FMCG: 5 companies →Godavari Biorefineries against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)35.6 against a typical 38.1: cheaper than most peers (1st = cheapest).2nd of 5
- Sales growth+4.7% against a typical +10.1% from a year earlier.4th of 5
- Share price, 3 months−22.1% against a typical −11.8%.4th of 5
- Size₹ 1,047.4 Cr. market value against a typical ₹ 3,847.3 Cr. (1st = largest).3rd of 4
Latest announcements
Exchange filings and their impact on the company.
- US cancer-drug patent granted with no 12-month sales impact but long-term IP upside.
Godavari Biorefineries said its US patent application for 5-Hydroxy-1,4-Naphthalenedione for use in treatment of cancer has been granted. The patent covers a novel class of compounds that inhibit cancer and cancer stem cells, with potential in breast and prostate cancers. There is no product launch or licensing deal yet, so no near-term sales impact.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated BBB+ by CARE- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE BBB+ | Stable | 17 Mar 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 17 Mar 2026 | Reaffirmed | CARE BBB+ | — | CARE | ₹ 835.83 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 4 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 5 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 22 May 2026 | Financial Results | To consider and approve the financial results for the quarter and year ended on March 31, 2026 |
| 13 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 11 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 7 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 24 May 2025 | Financial Results | To consider and approve the financial results for the period ended March 31, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 239 | 398 | 615 | 523 | 321 | 447 | 580 | 533 | 431 | 460 | 564 | 558 |
| Expenses | 271 | 353 | 501 | 535 | 354 | 411 | 467 | 527 | 439 | 417 | 478 | 557 |
| Operating Profit | −32 | 45 | 114 | −12 | −33 | 36 | 112 | 6 | −8 | 43 | 86 | 1 |
| OPM % | −13% | 11% | 18% | −2.3% | −10% | 8% | 19% | 1.1% | −1.8% | 9% | 15% | 0.1% |
| Other Income | 1 | 2 | 11 | 3 | 1 | 4 | 9 | 1 | −23 | −6 | 9 | 2 |
| Interest | 20 | 18 | 20 | 20 | 20 | 19 | 13 | 15 | 12 | 10 | 11 | 14 |
| Depreciation | 15 | 16 | 14 | 13 | 12 | 12 | 13 | 14 | 14 | 14 | 14 | 14 |
| Profit before tax | −65 | 13 | 91 | −42 | −64 | 8 | 96 | −22 | −57 | 13 | 70 | −26 |
| Tax % | 0% | −201% | 28% | −37% | 17% | 32% | 25% | −28% | −27% | 39% | 25% | −25% |
| Net Profit | −65 | 38 | 65 | −26 | −75 | 6 | 72 | −16 | −42 | 8 | 53 | −19 |
| EPS in Rs | −15.53 | 9.16 | 15.54 | −6.23 | −17.88 | 1.13 | 14.06 | −3.13 | −8.13 | 1.61 | 10.33 | −3.78 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 5%
- 3 Years
- 0%
- TTM
- 7%
- 10 Years
- —
- 5 Years
- 5%
- 3 Years
- 18%
- TTM
- 318%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 2%
- 3 Years
- 1%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Prices are delayed and for information only. Nothing on this page is investment advice.